January 5, 2024 10:32 AM ESTUpdated 11:57 AM
Pharma
Marketing

IQVIA and Pro­pel aban­don merg­er af­ter FTC probe and in­junc­tion

Beth Snyder Bulik

Senior Editor

IQVIA is call­ing off its ac­qui­si­tion of Pro­pel Me­dia and health tech mar­keter Deep­In­tent. The com­pa­nies agreed to aban­don the deal af­ter an FTC probe …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times